Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary ...

List today: Pharming Group N.V. PHAR: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current ...

This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to ...

Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction ...

'Pharming' attacks using sophisticated botnets are growing at an alarming rate, and new forms of authentication are needed to protect e-mail originators and Web sites.

Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) today announced The Lancet has published data from a Phase II, double-blind, placebo-controlled, randomized clinical ...

Pharming's Q2/19 results beat expectations for a second quarter in a row. Turnover is confirming that earlier perceived advantages for competition in the HAE marketplace were misguided. Huge ...

Chasin expects this first-generation phishing to move toward pharming, which involves Trojans, worms, or other technology that attack the browser address bar.

Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. announces that the Company’ s 2025 Annual General Meeting of Shareholders will be held on Wednesday June 11, 2025, at 14:00 CEST. The ...

Pharming Group reports third quarter 2023 financial results. Third quarter 2023 revenues increased 23% to US $66.7 million, compared to the third quarter 2022, driven by RUCONEST ® revenue and ...

Environmentalists worry about "bio-pharming" -- the creation of grain varieties for drug research. Regular corn and soybean crops could become contaminated, say groups such as Greenpeace ...